Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus

Molecular Therapy

Volumn 8, Issue 3, 2003, Pages 449-458

  Kanerva, Anna ^a,d,e,f   Zinn, Kurt R ^b   Chaudhuri, Tandra R ^b   Lam, John T ^a   Suzuki, Kaori ^a,g   Uil, Taco G ^a,h   Hakkarainen, Tanja ^a,i   Bauerschmitz, Gerd J ^a   Wang, Minghui ^a   Liu, Bin ^a   Cao, Zhihong ^b   Alvarez, Ronald D ^c   Curiel, David T ^a   Hemminki, Akseli ^a,d,e  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f JORVI HOSPITAL   (Finland)

^g MAYO CLINIC   (United States)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Adenovirus; Biological therapy; Gene therapy; Ovarian neoplasms; Virus replication

Indexed keywords

INTEGRIN; ONCOLYTIC VIRUS; VIRUS ONCOLYSATE; VIRUS RECEPTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; CANCER THERAPY; CARCINOMATOUS PERITONITIS; CELL KILLING; CONTROLLED STUDY; COXSACKIE VIRUS; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; FEMALE; GENE CONSTRUCT; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMAGING SYSTEM; IN VIVO STUDY; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; OVARY ADENOCARCINOMA; OVARY CANCER; OVARY CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PURIFICATION; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; SEROTYPE; SPHEROID CELL; STATISTICAL SIGNIFICANCE; TARGET CELL; TOXICITY TESTING; TUMOR CELL; VIRUS INFECTIVITY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; COXSACKIEVIRUS;

EID: 10744222544     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00200-4     Document Type: Article

References (42)

1. Vorburger, S. A., and Hunt, K. K. (2002). Adenoviral gene therapy. Oncologist 7: 46-59.
2. Sandmair, A. M., et al. (2000). Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. 11: 2197-2205.
3. Bauerschmitz, G. J., Barker, S. D., and Hemminki, A. (2002). Adenoviral gene therapy for cancer: From vectors to targeted and replication competent agents. Int. J. Oncol. 21: 1161-1174.
4. Hemminki, A., and Alvarez, R. D. (2002). Adenoviruses in oncology: A viable option? BioDrugs 16: 77-87.
5. Kanerva, A., et al. (2002). Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. 8: 275-280.
6. Kanerva, A., et al. (2002). Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. 5: 695-704.
7. Miller, C. R., et al. (1998). Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58: 5738-5748.
8. Cripe, T. P., et al. (2001). Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 61: 2951-2960.
9. Hemmi, S., Geertsen, R., Mezzacasa, A., Peter, I., and Dummer, R. (1998). The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum. Gene Ther. 9:2363-2373.
10. Anders, M., et al. (2002). Expression and regulation of the coxsackie-and-adenovirus receptor (CAR) in premalignant lesions and advanced neoplasms. Mol. Ther. 5: S214.
11. Stevenson, S. C., Rollence, M., White, B., Weaver, L., and McClelland, A. (1995). Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J. Virol. 69: 2850-2857.
12. Kirn, D., Martuza, R. L., and Zwiebel, J. (2001). Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. 7: 781-787.
13. Khuri, F. R., et al. (2000). A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6: 879-885.
14. Bischoff, J. R., et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376.
15. Fueyo, J., et al. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19: 2-12.
16. Heise, C., et al. (2000). An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6: 1134-1139.
17. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3: 639-645.
18. Sherr, C. J. (1996). Cancer cell cycles. Science 274: 1672-1677.
19. Douglas, J. T., Kim, M., Sumerel, L. A., Carey, D. E., and Curiel, D. T. (2001). Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res. 61: 813-817.
20. Hemminki, A., Dmitriev, I., Liu, B., Desmond, R. A., Alemany, R., and Curiel, D. T. (2001). Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res. 61: 6377-6381.
21. Suzuki, K., Fueyo, J., Krasnykh, V., Reynolds, P. N., Curiel, D. T., and Alemany, R. (2001). A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res. 7: 120-126.
22. Bauerschmitz, G. J., et al. (2002). Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res. 62: 1266-1270.
23. Shinoura, N., et al. (1999). Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res. 59: 3411-3416.
24. Nemunaitis, J., et al. (2001). Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19: 289-298.
25. Kirn, D. (2001). Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther. 8: 89-98.
26. Hemminki, A., et al. (2001). An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol. Ther. 4: 223-231.
27. Arap, W., Pasqualini, R., and Ruoslahti, E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380.
28. Peng, K.-W., TenEyck, C. J., Galanis, E., Kalli, K. R., Hartmann, L. C., and Russell, S. J. (2002). Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 62: 4656-4662.
29. Hemminki, A., et al. (2002). In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J. Natl. Cancer Inst. 94: 741-749.
30. Hemminki, A., Wang, M., Desmond, R. A., Strong, T. V., Alvarez, R. D., and Curiel, D. T. (2002). Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum. Gene Ther. 13: 1505-1514.
31. Vasey, P. A., et al. (2002). Phase I trial of intraperitoneal injection of the E1B-55-kD-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 20: 1562-1569.
32. Buller, R. E., et al. (2002). A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 9: 553-566.
33. Gambhir, S. S., Barrio, J. R., Herschman, H. R., and Phelps, M. E. (1999). Assays for noninvasive imaging of reporter gene expression. Nucl. Med. Biol. 26: 481-490.
34. Adams, J. Y., et al. (2002). Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat. Med. 8: 891-897.
35. Rehemtulla, A., et al. (2000). Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2: 491-495.
36. Nyati, M. K., et al. (2002). The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther. 9: 844-849.
37. Yu, D., Wolf, J. K., Scanlon, M., Price, J. E., and Hung, M. C. (1993). Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 53: 891-898.
38. Barker, S. D., et al. (2001). An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol. Oncol. 82: 57-63.
39. Lam, J. T., et al. (2003). Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Ther. 10: 377-387.
40. Uil, T. G., et al. (2003). Generation of an adenoviral vector containing an addition of a heterologous ligand to the serotype 3 fiber knob. Cancer Gene Ther. 10: 121-124.
41. Suzuki, K., Alemany, R., Yamamoto, M., and Curiel, D. T. (2002). The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin. Cancer Res. 8: 3348-3359.
42. Rosenfeld, M. E., Feng, M., Michael, S. I., Siegal, G. P., Alvarez, R. D., and Curiel, D. T. (1995). Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin. Cancer Res. 1: 1571-1580.